GIL BINARAO: Open Payments
NPI 1356322085 · GALAX, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$861 in 43 payments from 9 companies in 2025. Trend: 2023 $219 · 2024 $360 · 2025 $861
Food & beverage: $861
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $207 |
| Alkermes, Inc. | 10 | $163 |
| Lundbeck LLC | 7 | $151 |
| Janssen Pharmaceuticals, Inc | 4 | $102 |
| E.R. Squibb & Sons, L.L.C. | 4 | $100 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| ABBVIE INC. | 2 | $30 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
Products named: CAPLYTA, ARISTADA, ABILIFY MAINTENA, INVEGA SUSTENNA, COBENFY, REXULTI, VRAYLAR, HETLIOZ.
Industry payments across VA — which companies pay providers there.
